Sakshi Laller’s Post

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Thank you to the esteemed industry leaders and experts – Alaa Darwish, Dr Srikanth Rajagopal, Mohamed Amir, Firat Incioglu, Rina Chotai, and Hasan Kapar – for joining us at the Waldorf Astoria DIFC in Dubai for a thought-provoking roundtable discussion on "Unlocking the Market: Strategies for Pharmaceutical Pricing, Access, and Tenders in the GCC" earlier this month. The event provided a valuable platform to examine the critical role of national tenders in improving access to safe and effective medicines across the region. Experts engaged in an insightful dialogue on the current state of tender practices, delving into the evolution of these systems and their impact on the pharmaceutical industry, particularly in relation to various drug types. The conversation also focused on identifying key principles and best practices for designing a national tender system that ensures fair pricing, accessibility, and operational efficiency. Stay tuned for a report highlighting the key discussion topics and emerging trends. Discover more about Clarivate’s market-leading intelligence and transformative data technology here: https://lnkd.in/gD-vvkum #Pharmaceuticals #MarketAccess #Healthcare #Tenders #PharmaStrategy #HealthcareInnovation #Dubai

Sanofi CD38 Isatuximab is approved by Chinese FDA today, using Hainan Real World Data as key evidence (not supporting evidence). Hainan province is called “RWE Heaven”, set by Chinese FDA as a testbed of bringing your drugs or medical advices approved overseas to China market, with RWE only. It saves sponsor times and money, and brings new drugs to Chinese patients much faster. Ruijin hospital, a top research hospital in China, is behind this RWE work. Parexel and Ruijin Hospital became strategic partners in 2024, exploring RWE together, in Hainan.

Great opening panel at the World Orphan Drug Congress Europe with Elisabetta Zanon, Fabienne Bartoli, Toon Digneffe, Virginie Bros-Facer and Stelios Kympouropoulos The session built upon the recent report of former European Central Bank President Mario Draghi on the competitiveness of the European Union: https://lnkd.in/eSRtR9zg 📖 The report highlighted the need for Europe to remain competitive, also in the space of #pharmaceuticals. ⚡️ Increasingly, investments in healthcare and pharmaceutical innovation - also for rare diseases - are directed away from Europe. 🚧 Pricing and reimbursement of (orphan) drugs plays a key role here: there is an urgent need for European Member States to reduce investor uncertainties after marketing authorisation. 🚦 Depending on where in Europe you live, access to innovative therapies targeting rare diseases may be delayed by years (!) compared to other European Member States. ⚡️This is bad news for #Europe’s economy, and therefore European healthcare budgets. And not the least: bad news for patients. How should we improve our investments in #healthcare, especially for #rarediseases? 👉 Deserves joint procurement for orphan drugs further exploration? 👉 Should Member States enhance their pathways for early and alternative access to #orphandrugs? #wodc2024 #wodceurope #lifesciences #marketaccess #patientaccess #drugpricing

🌟Navigating the UAE Pharmaceutical Terrain 🌟   Operating a pharmaceutical business in the UAE presents a unique set of challenges, from navigating regulatory frameworks to understanding consumer behavior. Morphosis specializes in guiding clients through this intricate terrain, providing strategic insights and meticulous planning to ensure seamless execution. With a deep understanding of the local landscape, Morphosis empowers brands to overcome obstacles and thrive in a competitive market. 🔊 Morphosis, a pioneering marketing firm led by industry veterans Muhammad Usman Qaiser and Rija Nawab. With a wealth of experience spanning both the UAE and Pakistan’s pharmaceutical markets, Morphosis is redefining how brands connect and thrive in the competitive healthcare landscape of the UAE. Read the complete Article about Morphosis: https://lnkd.in/dANbkbwm #BusinessinUAE, #healthnews, #MarketingServices, #pharmaceuticalsinUAE, #PharmaUAE, #UAE

Pharmaceutical innovation is a true hope to improve the life of patients and contributes to a more efficient healthcare system and a robust economy as a sector of accelerated development. During the panel of Greek Economic Summitt organized by #AmChamGR we discussed that for Greece, time to take decisions to support pharmaceutical innovation is now.

The Power of Real-World Evidence: Bringing Everyday Health Data to Drug Approvals 🌟 Exciting news in the world of osteoporosis treatment! 🌟 Discover how Real-World Evidence (RWE) played a crucial role in the approval of abaloparatide (Eladynos) in the EU. This case study highlights the evolving acceptance of RWE in regulatory decisions, ensuring patient safety and fostering innovation. 📊🔬 #Osteoporosis #RealWorldEvidence #Pharma #RegulatoryAffairs #HealthcareInnovation #EMA #FDA #Abaloparatide #Eladynos https://lnkd.in/dMVU7K_s

#MENA’s #pharmaceutical #market is expected to be worth $52.4 billion by the end of 2024 and could grow to $59.9 billion by 2028, according to Fitch Solutions. This growth potential is being supported by the efforts of several countries to expand their #universal #healthcare #coverage, including #Morocco, which has been implementing major #health system reforms since 2020 and aims to have 100% #health coverage by 2025, according to The World Bank. Having been in the market for over 90 years, Moroccan pharmaceutical company, Cooper Pharma, is playing a role in these big plans. “We’re always looking for opportunities. We plan to reinforce our presence and further grow in our home country and beyond,” says Ayman Cheikh-Lahlou, Chairman and CEO of Cooper Pharma. Cooper Pharma’s business covers both manufacturing and commercial activities, with a network of nine fully-owned pharmaceutical manufacturing sites in the U.A.E., Saudi Arabia, Spain, the Czech Republic, Cote d’Ivoire, Rwanda, and Morocco. The company manufactured around 70 million packets of tablets and vials of medication in 2023, but this is still much less than it can do. Its total capacity stands at 120 million packs, and the CEO is determined to hit the maximum soon. As of 2023, Cooper Pharma had a market share of 11% by units in Morocco, explains Cheikh-Lahlou, as he emphasizes that the company intends to either establish new manufacturing capacities or acquire existing facilities in the near future. #Morocco allocated about $3.1 billion to its #health and social protection sector for 2024, marking a significant 55% increase from the 2021 budget. The government is also linking IT systems and hospitals under the Ministry of Health and Social Protection through a national database as part of a new integrated vision for upgrading the #health system, in line with the commitments of its 2021-2026 government program. To achieve its #healthcare #coverage goals, collaborative efforts have become crucial for Morocco, not only between the country’s government and private sector but also with international institutions. In 2023, The World Bank approved a $450 million program to support the government of #Morocco in implementing its ambitious reforms and help strengthen the #health system in underserved areas. Last year also saw the launch of the #Morocco- World Health Organization cooperation strategy 2023-2027. Marina Hartman Olivella

Thirteen impactful medicines that would be suitable for joint HTA have been identified by the Beneluxa Initiative (see accompanying table). The candidates were selected from an initial list of more than 200 pipeline drugs (status as of January 2024) included in the “High Impact Reports” of the International Horizon Scanning Initiative—a spin-off from Beneluxa. Criteria such as new chemical entity status and the potential to be a game changer in clinical prescribing practice were used to compile the shortlist.   Beneluxa would be interested in conducting full joint assessments for the selected drugs. If developers of these agents are interested in the possibility of joint HTA, Beneluxa can offer an exploratory meeting.   The collaboration emphasises that this list is by no means exclusive: developers of other drugs are invited to enquire about cross-border HTA. #Beneluxa #jointHTA

🌍 Join Us in Transforming Healthcare Access in Africa 🌍 At MedNord AB, we’re driven by a powerful vision: making high-quality, affordable healthcare accessible across Africa. With our robust distribution network and established partnerships in the region, we’re ready to help pharmaceutical companies reach new, high-demand markets. Why Partner with MedNord AB? Extensive Market Reach: Our deep local insights and established partnerships enable smooth, scalable entry into diverse African regions. Rapid Growth Potential: The demand for essential medications, chronic disease treatments, and innovative therapies is rising across the continent. Proven Expertise: From navigating regulatory requirements to providing efficient distribution, we have the know-how to support successful market expansion. We’re seeking pharmaceutical companies and healthcare innovators eager to make a difference and expand their global reach. If your company is ready to seize the opportunity of tapping into Africa’s growing healthcare market, let’s collaborate. 🤝 Ready to take the next step? Partner with MedNord AB to expand your reach and bring transformative healthcare solutions to the African market. Let’s explore how we can make a powerful impact together. #HealthcareInnovation #PharmaceuticalPartnership #GlobalExpansion #MedNordAB